Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Vildagliptin is an oral anti-diabetic agent. This is a 24-week study to assess the efficacy
on HbA1c of 100 mg vildagliptin once daily as compared to placebo as add-on to metformin in
patients with type 2 diabetes inadequately controlled with metformin.